Evidence map›Paper›PMID 32798276›Full record

ReviewJournal of clinical pharmacology2020

Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy.

Engie Salama, Ahizechukwu C Eke, Brookie M Best, Mark Mirochnick, Jeremiah D Momper

Abstract readReview
In one paragraph

Review in Journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. A practical clinical guide to counselling on and managing contraception, pre-conception planning, and menopause for women living with HIV.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2021
    Article
  10. Considerations for the Use of AAV-based Gene Therapy in HIV-Positive Individuals With Haemophilia.Haemophilia : the official journal of the World Federation of Hemophilia
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Engie SalamaSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.
Ahizechukwu C EkeDivision of Maternal Fetal Medicine & Clinical Pharmacology, Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-0070-9840
Brookie M BestSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.
Mark MirochnickDivision of Neonatology, Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts, USA.
Jeremiah D MomperSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Johns Hopkins Women's Reproductive Health Research Career Development ProgramK12HD103036 · NICHD · JOHNS HOPKINS UNIVERSITY · PI SATIN, ANDREW J. · 2020 to 2024
$1.5M
NIAID NIH HHS P30 AI094189NICHD NIH HHS K12 HD103036
6 · The paper itself

Abstract

Pharmacokinetic boosting of antiretroviral (ARV) therapies with either ritonavir or cobicistat is used to achieve target drug exposure, lower pill burden, and provide simplified dosing schedules. Several ARVs require boosting, including the integrase inhibitor elvitegravir as well as protease inhibitors such as darunavir, atazanavir, and lopinavir. The use of boosted regimens in pregnant women living with HIV has been studied for a variety of ARVs; however, a recent recommendation by the US Food and Drug Administration advised against cobicistat-boosted regimens in pregnancy due to substantially lower drug exposures observed in clinical pharmacokinetic studies. The objectives of this article are to review pharmacokinetic enhancement of ARVs with ritonavir and cobicistat during pregnancy and postpartum, describe clinical implications, and provide recommendations for future research.

Indexed as

Anti-HIV AgentsCobicistatCytochrome P-450 CYP3A InhibitorsDrug Therapy, CombinationFemaleHIV InfectionsHumansPostpartum PeriodPregnancyRitonavirAnti-HIV AgentsCobicistatCytochrome P-450 CYP3A InhibitorsRitonavircobicistatdrug metabolismHIVpharmacokineticspregnancyritonavir

Identifiers

PMID32798276
PMCPMC8227837

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.